Instruction for use: Humulin L

ATX CodeA10AC Medium-acting insulins and their analogs for injectable administration

Active substance Insulin biphasic [human biosynthetic]

Pharmacological group

Insulins

Nosological classification (ICD-10)Z31.1 Artificial insemination

E10 Insulin-dependent diabetes mellitus

Decompensation of carbohydrate metabolism, Diabetes mellitus, Diabetes insulin sugar, Diabetes mellitus type 1, Diabetic ketoacidosis, Insulin-dependent diabetes, Insulin-dependent diabetes mellitus, Coma hyperosmolar non-ketoacidotic, Labile form of diabetes mellitus, Violation of carbohydrate metabolism, Type 1 diabetes mellitus, Type I diabetes mellitus, Insulin-dependent diabetes mellitus, Type 1 diabetes mellitus

E11 Non-insulin-dependent diabetes mellitus

Acetonuric diabetes, Decompensation of carbohydrate metabolism, Diabetes insulin-independent sugar, Diabetes sugar type 2, Type 2 Diabetes, Non-insulin-dependent diabetes, Non-insulin dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Insulin resistance, Insulin resistant diabetes mellitus, Coma lactobacillus diabetic, Violation of carbohydrate metabolism, Type 2 diabetes mellitus, Diabetes mellitus type II, Diabetes mellitus in adulthood, Diabetes mellitus in old age, Diabetes insulin-independent, Diabetes mellitus type 2, Sugar insulin-independent diabetes type II

Composition and form of release

1 ml of insulin-zinc suspension for injection contains human insulin 40 or 100 units; In bottles of 10 ml.

Characteristic

Medium-duration drug.

pharmachologic effect

Pharmacological action - hypoglycemic.

Increases the absorption of glucose by tissues. Prevents the breakdown of glycogen in the liver, stimulates its formation.

Clinical Pharmacology

The effect develops in 30 minutes, reaches a maximum 4-16 hours after administration and lasts 24 hours.

indications

Insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus.

Contraindications

Hypoglycemia.

Side effects

Hypoglycemia, lipodystrophy, allergic reactions.

Interaction

Hypoglycemic effect is enhanced by MAO inhibitors, alcohol, nonselective beta-blockers, sulfonamides; Reduce - oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics.

Dosing and Administration

P / ê, in / m; The injection site should be changed. The dose is determined individually. When monotherapy is administered 1-2 times a day. If necessary, a combination with Humulin Regular is possible.

Precautionary measures

When transferring patients from animal insulin to human, it may be necessary to reduce the dosage and / or change the ratio of drugs of different duration of action. The dose decreases immediately or gradually (within a few weeks). The risk of developing hypoglycemia in switching from one type of insulin to another is not significant if the daily dose of the drug is less than 40 units.

storage conditions

In the refrigerator, at a temperature of 2-8 ° C (do not freeze).

Keep out of the reach of children.

Shelf life

1,5 years.

Do not use after the expiry date printed on the package.